Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 251

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Sodium Nitroprusside: Twenty Years and Counting

Friederich, Jeffrey A., Butterworth, John F. · 1995 · Anesthesia & Analgesia

Abstract

Almost from its first reported use in humans in 1928 [1], sodium nitroprusside (SNP) has been characterized as either villain or hero, depending on the clinician's assessment of the drug's risk-benefit ratio regarding cyanide toxicity. Not until 1955 was the safety of short-term SNP infusion established for treatment of severe hypertension [2]. Nevertheless, owing to difficulties with chemical preparation, SNP was not released for clinical use in the United States until 1974. Despite its immediate widespread adoption and apparent safety, concern remained about its potential for toxicity. Recently, the routine use of SNP in doses exceeding 2 micro gram centered dot kg-1 centered dot min-1 or at smaller doses when continued for >24 h has been challenged [3-5]. In 1991, the Food and Drug Administration, yielding to outside pressure as outlined by Robin and McCauley [5], approved new labeling for SNP which contained greater detail about the risk of cyanide toxicity, based on knowledge gained from clinical use and limited research since SNP's initial approval 17 yr earlier [6]. In addition to renewed warnings about SNP toxicity, several studies have examined whether prophylactic administration of various drugs to patients requiring SNP infusions would ameliorate or eliminate cyanide toxicity [7-11]. In short, although beset with controversy, SNP remains a commonly used drug, with total sales in the United States in 1993 (the latest year for which complete data are available) exceeding $2 million (Mr. Mark Sebree, Abbott Laboratories, personal communication, 1995). In this review we discuss the current indications and contraindications to SNP, evaluate its toxicity, and provide a plan for its rational use. Chemical Properties and Mechanism of Action SNP (disodium pentacyanonitrosylferrate(2-)dihydrate, Na2 Fe(CN) (5) NO centered dot 2H2 O) is comprised of a ferrous ion center complexed with five cyanide moieties and a nitrosyl group. The molecule is 44% cyanide by weight and soluble in water. Once infused, SNP can interact with oxyhemoglobin, dissociating immediately and forming methemoglobin while releasing cyanide and nitric oxide [12,13]Figure 1. Most investigators recognize nitric oxide (NO) as endothelium-derived relaxing factor, the active mediator responsible for the direct, vasodilating effect of SNP, although some would argue for a related nitrosothiol instead [14-16]. In contrast to the organic nitrates (e.g., nitroglycerin) which require the presence of highly specific thiol-containing compounds to generate NO, SNP spontaneously generates this product, thus functioning as a prodrug [14].Figure 1: Primary pathways of SNP metabolism. SNP = sodium nitroprusside; CN- = cyanide radical; NO sup. = nitric oxide radical; METHGB = methemoglobin; CYANOHGB = cyanomethemoglobin; OXYHGB = oxyhemoglobin.Once released, NO activates the enzyme guanylate cyclase found within vascular smooth muscle Figure 2, resulting in increased intracellular concentrations of cyclic guanosine monophosphate, which inhibits calcium entry into vascular smooth muscle cells and may increase calcium uptake by the smooth endoplasmic reticulum to produce vasodilation [14]. Recent, controversial evidence suggests that NO may possess a direct myocardial effect of unknown clinical significance [14,17].Figure 2: Mechanism of action of SNP. A decrease in intracellular free calcium concentration leads to relaxation. SNP = sodium nitroprusside; CN- = cyanide radical; NO sup. = nitric oxide radical; Ca2+ = calcium ion; PM = plasma membrane; GC = guanylate cyclase; GTP = guanosine triphosphate; cGMP = cyclic guanosine monophosphate; SER = smooth endoplasmic reticulum circle plus = promotes; circle minus = inhibits.Metabolism and Toxicology SNP's spontaneous breakdown products, NO sup. and CN-, are rapidly cleared by nonenzymatic means, through interaction with sulfhydryl groups on proteins in surrounding tissue and in erythrocytes [2,12,13,18,19]Figure 1. Five cyanide radicals are released by each SNP molecule, which may immediately react with methemoglobin to produce cyanomethemoglobin [13]. Normal adult methemoglobin concentrations in blood (approximately 0.5% of all hemoglobin species) are capable of binding the cyanide released from 18 mg of SNP [8]. Cyanomethemoglobin remains in a dynamic equilibrium with free cyanide and is considered nontoxic [12,20]. Adverse effects from methemoglobinemia generated by SNP breakdown are rare, even in patients with congenital inability to convert methemoglobin to hemoglobin (i.e., methemoglobin reductase deficiency). The total SNP dose typically required to generate 10% methemoglobinemia exceeds 10 mg/kg (i.e., 10 micro gram centered dot kg-1 centered dot min-1 for more than 16 h) [18]. Patients receiving such doses of SNP who present with evidence of impaired oxygenation despite adequate cardiac output (CO) and PaO2 should have methemoglobinemia included in their differential diagnosis and measurement of methe

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00000539-199507000-00031

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 251

Metadata

Authors
Friederich, J. A., & Butterworth, J. F.
Venue
Anesthesia & Analgesia
Published
1995-07
Volume
81
Issue
1
Pages
152-162
ISSN
0003-2999 (ISSN-L)
OpenAlex
W2058687959
Cited by
251
References
2
FWCI
6.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sodium Nitroprusside: Twenty Years and Counting. https://app.cochat.ai/papers/10.1097/00000539-199507000-00031
The paper
Friederich, J. A., & Butterworth, J. F. (1995). Sodium Nitroprusside: Twenty Years and Counting. Anesthesia & Analgesia. https://doi.org/10.1097/00000539-199507000-00031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.